Plasma Biomarkers and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: New Tools for Better Patient Selection?

被引：25

作者：

Costantini, Adrien ^{[1
,2
]}

Kamga, Paul Takam ^{[2
]}

Dumenil, Coraline ^{[1
,2
]}

Chinet, Thierry ^{[1
,2
]}

Emile, Jean-Francois ^{[2
,3
]}

Leprieur, Etienne Giroux ^{[1
,2
]}

机构：

[1] Hop Ambroise Pare, AP HP, Dept Resp Dis & Thorac Oncol, F-92100 Boulogne, France

[2] Univ Paris Saclay, UVSQ, EA BECCOH 4340, F-92100 Boulogne, France

[3] Hop Ambroise Pare, AP HP, Dept Pathol, F-92100 Boulogne, France

来源：

CANCERS | 2019年 / 11卷 / 09期

关键词：

non-small cell lung cancer; plasma; biomarkers; immune checkpoint inhibitor; DEATH-LIGAND; 1; PD-L1; EXPRESSION; GRANZYME-B; OPEN-LABEL; DOCETAXEL; NIVOLUMAB; TUMOR; ATEZOLIZUMAB; MULTICENTER;

D O I：

10.3390/cancers11091269

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Immune checkpoint inhibitors (ICIs) have transformed the treatment landscape for patients with non-small cell lung cancer (NSCLC). Although some patients can experience important response rates and improved survival, many others do not benefit from ICIs developing hyper-progressive disease or immune-related adverse events. This underlines the need to select biomarkers for ICIs use in order to better select patients. There is currently no universally validated robust biomarker for daily use of ICIs. Programmed death-ligand 1 (PD-L1) or tumor mutational burden (TMB) are sometimes used but still have several limitations. Plasma biomarkers are a promising approach in ICI treatment. This review will describe the development of novel plasma biomarkers such as soluble proteins, circulating tumor DNA (ctDNA), blood TMB, and blood microbiome in NSCLC patients treated with ICIs and their potential use in predicting response and toxicity.

引用

页数：14

共 53 条

[1] Blood Microbiota Dysbiosis Is Associated with the Onset of Cardiovascular Events in a Large General Population: The DESIR Study [J].

Amar, Jacques ;

Lange, Celine ;

Payros, Gaelle ;

Garret, Celine ;

Chabo, Chantal ;

Lantieri, Olivier ;

Courtney, Michael ;

Marre, Michel ;

Charles, Marie Aline ;

Balkau, Beverley ;

Burcelin, Remy .

PLOS ONE, 2013, 8 (01)

[2] Intestinal mucosal adherence and translocation of commensal bacteria at the early onset of type 2 diabetes: molecular mechanisms and probiotic treatment [J].

Amar, Jacques ;

Chabo, Chantal ;

Waget, Aurelie ;

Klopp, Pascale ;

Vachoux, Christelle ;

Bermudez-Humaran, Luis G. ;

Smirnova, Natalia ;

Berge, Mathieu ;

Sulpice, Thierry ;

Lahtinen, Sampo ;

Ouwehand, Arthur ;

Langella, Philippe ;

Rautonen, Nina ;

Sansonetti, Philippe J. ;

Burcelin, Remy .

EMBO MOLECULAR MEDICINE, 2011, 3 (09) :559-572

[3] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer [J].

Antonia, S. J. ;

Villegas, A. ;

Daniel, D. ;

Vicente, D. ;

Murakami, S. ;

Hui, R. ;

Yokoi, T. ;

Chiappori, A. ;

Lee, K. H. ;

de Wit, M. ;

Cho, B. C. ;

Bourhaba, M. ;

Quantin, X. ;

Tokito, T. ;

Mekhail, T. ;

Planchard, D. ;

Kim, Y. -C. ;

Karapetis, C. S. ;

Hiret, S. ;

Ostoros, G. ;

Kubota, K. ;

Gray, J. E. ;

Paz-Ares, L. ;

de Castro Carpeno, J. ;

Wadsworth, C. ;

Melillo, G. ;

Jiang, H. ;

Huang, Y. ;

Dennis, P. A. ;

Ozguroglu, M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) :1919-1929

[4] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[5] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[6] Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study [J].

Cabel, L. ;

Riva, F. ;

Servois, V. ;

Livartowski, A. ;

Daniel, C. ;

Rampanou, A. ;

Lantz, O. ;

Romano, E. ;

Milder, M. ;

Buecher, B. ;

Piperno-Neumann, S. ;

Bernard, V. ;

Baulande, S. ;

Bieche, I. ;

Pierga, J. Y. ;

Proudhon, C. ;

Bidard, F. -C. .

ANNALS OF ONCOLOGY, 2017, 28 (08) :1996-2001

[7] Clinical potential of circulating tumour DNA in patients receiving anticancer immunotherapy [J].

Cabel, Luc ;

Proudhon, Charlotte ;

Romano, Emanuela ;

Girard, Nicolas ;

Lantz, Olivier ;

Stern, Marc-Henri ;

Pierga, Jean-Yves ;

Bidard, Francois-Clement .

NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (10) :639-650

[8] First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer [J].

Carbone, D. P. ;

Reck, M. ;

Paz-Ares, L. ;

Creelan, B. ;

Horn, L. ;

Steins, M. ;

Felip, E. ;

van den Heuvel, M. M. ;

Ciuleanu, T. -E. ;

Badin, F. ;

Ready, N. ;

Hiltermann, T. J. N. ;

Nair, S. ;

Juergens, R. ;

Peters, S. ;

Minenza, E. ;

Wrangle, J. M. ;

Rodriguez-Abreu, D. ;

Borghaei, H. ;

Blumenschein, G. R. ;

Villaruz, L. C. ;

Havel, L. ;

Krejci, J. ;

Corral Jaime, J. ;

Chang, H. ;

Geese, W. J. ;

Bhagavatheeswaran, P. ;

Chen, A. C. ;

Socinski, M. A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (25) :2415-2426

[9] Heterogeneity of Tumor and Immune Cell PD-L1 Expression and Lymphocyte Counts in Surgical NSCLC Samples [J].

Casadevall, David ;

Clave, Sergi ;

Taus, Alvaro ;

Hardy-Werbin, Max ;

Rocha, Pedro ;

Lorenzo, Marta ;

Menendez, Silvia ;

Salido, Marta ;

Albanell, Joan ;

Pijuan, Lara ;

Arriola, Edurne .

CLINICAL LUNG CANCER, 2017, 18 (06) :682-+

[10] Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab [J].

Costantini, Adrien ;

Julie, Catherine ;

Dumenil, Coraline ;

Helias-Rodzewicz, Zofia ;

Tisserand, Julie ;

Dumoulin, Jennifer ;

Giraud, Violaine ;

Labrune, Sylvie ;

Chinet, Thierry ;

Emile, Jean-Francois ;

Leprieur, Etienne Giroux .

ONCOIMMUNOLOGY, 2018, 7 (08)

← 1 2 3 4 5 6 →